Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids
Jenessa A. Winston, Alissa J. Rivera, Jingwei Cai, Rajani Thanissery, Stephanie A. Montgomery, Andrew D. Patterson, Casey M. Theriot
Abstract
Clostridioides difficile infection (CDI) is associated with increasing morbidity and mortality posing an urgent threat to public health. Recurrence of CDI after successful treatment with antibiotics is high, thus necessitating discovery of novel therapeutics against this enteric pathogen. Administration of the secondary bile acid ursodeoxycholic acid (UDCA; ursodiol) inhibits the life cycles of various strains of C. difficile in vitro , suggesting that the FDA-approved formulation of UDCA, known as ursodiol, may be able to restore colonization resistance against C. difficile in vivo .
Topics & Concepts
Ursodeoxycholic acidBiologyBile acidMicrobiologyDeoxycholic acidBile Salt Export PumpTLR2MetabolomePharmacologyInnate immune systemImmune systemImmunologyBiochemistryMetaboliteTransporterGeneClostridium difficile and Clostridium perfringens researchHelicobacter pylori-related gastroenterology studiesMicroscopic Colitis